“We see two business opportunities arising from this acquisition. First, to continue driving TriPath Imaging’s cervical cancer screening business, and second, to align their innovative new technologies with BD’s existing business strategies,” said Vincent A. Forlenza, BD Executive Vice President. “This acquisition is a natural complement to ongoing bio-marker research programs within BD, with the potential to leverage BD instrumentation.”

As previously stated in BD’s August 14, 2006 press release relating to its submission of a proposal to acquire TriPath, the acquisition is expected to be minimally dilutive to BD’s fiscal 2007 earnings (excluding an anticipated charge for in-process research and development). BD will provide guidance for fiscal 2007 during its fiscal fourth quarter earnings call on November 2, 2006.

BD senior management will address this announcement at two upcoming investor healthcare conferences. Remarks will be webcast live and can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay for one week from the date of the presentation. Vincent A. Forlenza, Executive Vice President, will present at the Thomas Weisel Partners Healthcare Conference 2006 today at 9:45 a.m. (ET). Edward J. Ludwig, Chairman, President and Chief Executive Officer, will present at the Bear Stearns 19^th Annual Healthcare Conference on Tuesday, September 12, 2006 at 2:00 p.m. (ET).

About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future performance, products or other events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; changes in healthcare or other governmental regulation; as well as other factors discussed in this press release and in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.